FDA Approves Jardiance Tablets for Adults with Type 2 Diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company have announced FDA has approved Jardiance (empagliflozin) tablets as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes (T2D). Jardiance is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine).

Jardiance, a once-daily, 10 mg or 25 mg tablet, is a sodium glucose co-transporter-2 (SGLT2) inhibitor. Jardiance works by blocking the reabsorption of glucose in the kidney, increasing glucose excretion and lowering blood glucose levels in adults with T2D who have elevated blood glucose levels.

"Many adults with type 2 diabetes still have difficulty controlling their blood sugar levels even with treatment. There is a critical need for new treatment options to help these patients," said Christophe Arbet-Engels, MD, PhD, vice president, metabolic-clinical development and medical affairs, BIPI. "Jrdiance is a new option that has been shown in clinical trials to reduce blood sugar levels. Although not approved for weight loss, modest weight loss was also observed in these clinical trials."

The FDA approval is based on results from a large clinical programme comprised of more than 10 multinational clinical trials and more than 13,000 adults with T2D. Phase III studies showed Jardiance significantly reduced hemoglobin A1C (a measure of average blood glucose over the past 2 to 3 months) and fasting blood sugar after 24 weeks as a stand-alone treatment or in combination with a range of background treatments, including metformin, sulfonylureas, insulin and pioglitazone. Although Jardiance is not approved for lowering weight or blood pressure, modest reductions in both weight and systolic blood pressure were observed in clinical trials.

The most common adverse reactions associated with Jardiance were urinary tract infections and vaginal yeast infections. Hypoglycemia was more commonly reported in patients treated with the combination of Jardiance and sulfonylurea or insulin.

"The FDA approval of Jardiance provides an exciting new option in the treatment of adults with type 2 diabetes and demonstrates our commitment to these patients, as it marks the third diabetes medicine to emerge from our alliance pipeline," said Enrique Conterno, president, Lilly Diabetes.